Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M403448200 on June 2, 2004

J. Biol. Chem., Vol. 279, Issue 33, 34240-34249, August 13, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An addition or correction has been published
Right arrow All Versions of this Article:
279/33/34240    most recent
M403448200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Milovic, S.
Right arrow Articles by Weigl, L. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Milovic, S.
Right arrow Articles by Weigl, L. G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Sensitivity of G Protein-activated K+ Channels toward Halothane Is Essentially Determined by the C Terminus*

Sergej Milovic{ddagger}, Bibiane Steinecker-Frohnwieser§, Wolfgang Schreibmayer§, and Lukas G. Weigl{ddagger}

From the {ddagger}Medical University of Vienna, Department of Anesthesia and Intensive Care Medicine (B), Währinger Gürtel 18–20, A-1090 Vienna, Austria and the §Institute for Medical Physics and Biophysics, Medical University of Graz, A-8010 Graz, Austria

G protein-activated K+ channels (GIRKs or Kir3.x) are targets for the volatile anesthetic, halothane. When coexpressed with the m2 acetylcholine (ACh) receptor in Xenopus oocytes, agonist-activated GIRK1F137S- and GIRK2-mediated currents are inhibited by halothane, whereas in the absence of ACh, high concentrations of halothane induce GIRK1F137S-mediated currents. To elucidate the molecular mechanism of halothane action on GIRK currents of different subunit compositions, we constructed deletion mutants of GIRK1F137S (GIRK1{Delta}363*) and GIRK2 (GIRK2{Delta}356) lacking the C-terminal ends, as well as chimeric GIRK channels. Mutated GIRK channels showed normal currents when activated by ACh but exhibited different pharmacological properties toward halothane. GIRK2{Delta}356 showed no sensitivity against the inhibitory action of halothane but was activated by halothane in the absence of an agonist. GIRK1{Delta}363* was activated by halothane more efficiently. Currents mediated by chimeric channels were inhibited by anesthetic concentrations that were at least 30-fold lower than those necessary to decrease GIRK2 wild type currents. Glutathione S-transferase pulldown experiments did not show displacement of bound G{beta}{gamma} by halothane, indicating that halothane does not interfere with G{beta}{gamma} binding. Single channel experiments revealed an influence of halothane on the gating of the channels: The agonist-induced currents of GIRK1 and GIRK2, carried mainly by brief openings, were inhibited, whereas higher concentrations of the anesthetic promoted long openings of GIRK1 channels. Because the C terminus is crucial for these effects, an interaction of halothane with the channel seems to be involved in the mechanism of current modulation.


Received for publication, March 29, 2004 , and in revised form, June 1, 2004.

* This work was supported by Grant 8266 from the Oesterreichische Nationalbank (to L. G. W.), Austrian Research Foundation Grants P17702-B09 (to L. G. W.), T124-B04 (to B. S.-F.), and SFB007/F708 (to W. S.), and Austrian Ministry of Science Grant UGP4 (to W. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed. Tel.: 43-1-40400-4147; Fax: 43-1-40400-6422; E-mail: lukas.weigl{at}univie.ac.at.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement